Gain of function of mutant p53 by coaggregation with multiple tumor suppressors-Reference-Cited by-同舟云学术

Gain of function of mutant p53 by coaggregation with multiple tumor suppressors

Published:2011-03-27 Issue:5 Volume:7 Page:285-295
ISSN:1552-4450
Container-title:Nature Chemical Biology
language:en
Short-container-title:Nat Chem Biol

Author:

Xu Jie,Reumers Joke,Couceiro José R,De Smet Frederik,Gallardo Rodrigo,Rudyak Stanislav,Cornelis Ann,Rozenski Jef,Zwolinska Aleksandra,Marine Jean-Christophe,Lambrechts Diether,Suh Young-Ah,Rousseau Frederic,Schymkowitz Joost

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology

Link

http://www.nature.com/articles/nchembio.546.pdf

Reference50 articles.

1. Aguzzi, A. & O'Connor, T. Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nat. Rev. Drug Discov. 9, 237–248 (2010).

2. Huo, Q. Protein complexes/aggregates as potential cancer biomarkers revealed by a nanoparticle aggregation immunoassay. Colloids Surf. B Biointerfaces 78, 259–265 (2010).

3. Maslon, M.M. & Hupp, T.R. Drug discovery and mutant p53. Trends Cell Biol. 20, 542–555 (2010).

4. Olivier, M. et al. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum. Mutat. 19, 607–614 (2002).

5. Ang, H.C., Joerger, A.C., Mayer, S. & Fersht, A.R. Effects of common cancer mutations on stability and DNA binding of full-length p53 compared with isolated core domains. J. Biol. Chem. 281, 21934–21941 (2006).

Cited by 437 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of N-Benzylpiperidinol derivatives as USP7 inhibitors against Hematology;Bioorganic Chemistry;2024-09

2. Mutant p53 Exploits Enhancers to Elevate Immunosuppressive Chemokine Expression and Impair Immune Checkpoint Inhibitors in Pancreatic Cancer;2024-08-30

3. Exploring the MRI and Clinical Features of P53-Mutated Hepatocellular Carcinoma;Journal of Hepatocellular Carcinoma;2024-08

4. Germline NGS targeted analysis in adult patients with sporadic adrenocortical carcinoma;European Journal of Cancer;2024-07

5. An engineered DNA aptamer-based PROTAC for precise therapy of p53-R175H hotspot mutant-driven cancer;Science Bulletin;2024-07